[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583894":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":52,"collaborators":54,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University of Sao Paulo General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group Monitoring","EXPERIMENTAL","After randomization, participants in the GM group will receive the Venu® SQ monitor (Garmin). All participants will receive guidance on how to use the ODI in the educational class, and at the end they will receive specific instructions for use of the devices they will receive (wearable monitor or pulse oximeter). After the first visit, GM participants will be contacted biweekly by telephone to obtain information on their clinical progress, where they will be asked about the number of exacerbations, respiratory symptoms, medication adherence, time of O2 use, and dyspnea symptoms (mMRC). Likewise, monthly contact will be made to obtain information on health factors associated with quality of life (K-BILD), CAT and EQ-5D-5L, and symptoms of anxiety and depression (HADS).",[13],"Behavioral: Group Monitoring",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","ACTIVE_COMPARATOR","For the GC, contact will only be monthly to obtain all the information mentioned above in addition to the HR and SpO2 measurements taken on the day of the telephone application.",[19],"Behavioral: Control Group",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"BEHAVIORAL","In the intervention group (IG), participants receive a HR and SPO2 monitor watch and a pulse oximeter and will be monitored every 15 days by a nurse to check for non-adherence and\u002For technical failure, and\u002For exacerbations, and monthly to apply questionnaires.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"In the control group (CG), participants receive only a pulse oximeter and will be monitored monthly by a nurse to administer the questionnaires.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Celso RF Carval, Diretor do Estudo","CONTACT","55 11 98415-3234","cscarval@usp.br",[36],{"facility":37,"status":38,"city":39,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP),","RECRUITING","São Paulo","05360-160","Brazil","BR",{"type":44,"coordinates":45},"Point",[46,47],-46.63611,-23.5475,{"lat":47,"lon":46},[50],{"name":51,"role":32,"phone":33,"phoneExt":25,"email":34},"Celso RF Carvalho, PhD",{"type":53,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[55],{"name":56,"class":57},"Air Liquide SA","INDUSTRY","100583894","impact-of-remote-vital-signs-monitoring-in-people-using-long-term-oxygen-therapy-100583894",false,"NCT06882265","Impact of Remote Vital Signs Monitoring in People Using Long-term Oxygen Therapy","Impact of Remote Vital Signs Monitoring in People Using Long-term Oxygen Therapy : a Randomized Clinical Trial","ILD; COPD","Inclusion Criteria:\n\n* Patients with a clinical, radiological and\u002For anatomopathological diagnosis of COPD and ILD according to the 2020 ATS\u002FJRS\u002FALAT guidelines;\n* Age over 18 years;\n* Clinical stability (absence of exacerbations or hospitalizations related to the underlying disease) for at least 6 weeks;\n* Patients who are on optimized drug therapy, including long-term home oxygen therapy (LTOT)\n* Have a smartphone compatible with the monitoring device;\n* Signing of the ICF to participate in the study.\n\nExclusion Criteria:\n\n* Presence of other concomitant lung diseases;\n* Myocardial infarction within four months prior to the start of the study, unstable angina or severe heart disease (NYHA functional class III-IV) and\u002For decompensated.\n* Patients who received a lung transplant during the study\n* Living outside the coverage area or moving out of state","ALL","18 Years","85 Years",{"count":70,"type":71},60,"ESTIMATED","INTERVENTIONAL",[74],"NA","Assess quality of life of patients using prolonged oxygen therapy",[77,78],"ILD","COPD",[80,81,77,78],"Quality of life","Monitoring remote","2025-03-11",{"date":84,"type":85},"2025-03-18","ACTUAL",{"date":87,"type":85},"2024-11-10",{"date":89,"type":71},"2025-12-15",{"name":5,"class":6},1]